USPTO 2015–2025 USPTO PatentsView US Corporation

Crinetics Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 27 granted patents across 6 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Crinetics ranks #11,225 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 6 technology areas.

#11,225
of 49,997 US assignees by volume
Top 44%
by Innovation Score (37.3/100)
20.8
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11225 · US Corporation #11,225 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 27 grants
  • UPPER-Q #11,225/49,997
  • PHOTO-FINISH Casper Sleep
  • CPC-NARROW A61P · 6 areas
  • INNOV-THIN 37.3/100
  • CLAIMS-DENSE 20.8 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Casper Sleep Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Crinetics’s 37.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Crinetics

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Crinetics's Innovation Score is 37.3/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Crinetics?

Each dot is one of Crinetics’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Crinetics’s own 20.8 claims/patent is ABOVE the 17.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Crinetics vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 26.92727.1 0510152025 Granted patents (volume) Avg claims / patent Co2pac Limited - 27, 17.93Co2pacCognyte Technologies Israel Ltd. - 27, 16.93Cognyte IsraelCoperion GMBH - 27, 17.89CoperionCPT Group GmbH - 27, 12.7CPT GroupCasper Sleep Inc. - 27, 5.44Casper SleepCenTrak, Inc. - 27, 21.22CentrakCequent Performance Products, Inc. - 27, 21.11Cequent Performan…Charm Sciences, Inc. - 27, 17.67Charm SciencesCrinetics Pharmaceuticals, Inc. - 27, 20.78Crinetics Pharmac…
Crinetics vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Crinetics's grants concentrate

Crinetics Pharmaceuticals, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 88.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (6 grants) versus a trough of 2 in 2019. By volume, Crinetics sits between Co2pac Limited and Charm Sciences, Inc..

Crinetics's three-year grant acceleration

Crinetics Pharmaceuticals, Inc. shows 9 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Crinetics's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Crinetics holds 27 patents at rank #11,209, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Crinetics

By rank, the assignees closest to #11,209 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Crinetics's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Crinetics, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Crinetics ranks #816 of 6,058 assignees by patent count in that subclass.

Crinetics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1234567 20182019202020212022202320242025 2
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Crinetics Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 3 11.1%
2019 2 7.4%
2020 6 22.2%
2021 5 18.5%
2022 3 11.1%
2023 4 14.8%
2024 2 7.4%
2025partial year 2 7.4%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Crinetics Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Crinetics Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.9% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #11,225 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Crinetics Pharmaceuticals, Inc. against Co2pac Limited, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 37.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.